OBJECTIVES: The aim of this study was to assess the standard uptake value in clinical stage I non-small cell lung cancer (NSCLC) and its correlation with pathological status and prognosis.
INTRODUCTION
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death and has a dismal prognosis. The treatment of patients with NSCLC is determined by the stage of disease. Despite advances in chemotherapy, surgery remains the only curative method. An accurate preoperative staging is very important in determining the appropriate treatment and in avoiding inappropriate thoracotomy. Positron emission tomography-computed tomography (PET-CT) is a safe, noninvasive tool for the evaluation of indeterminate pulmonary nodules and the staging of mediastinal lymph nodes and distant metastases. The PET-CT scan allows the most accurate staging in NSCLC [1] [2] [3] . The maximum standard uptake value (SUVmax) of a pulmonary tumour indicates its biological aggressiveness. Many previous studies have reported an association between a high SUVmax and poor prognoses [4] [5] [6] [7] [8] . Some recent studies have found that the preoperative SUVmax is not an independent predictor of the overall survival [9] . It is well known that the clinical stage does not fully predict the pathological stage. Identification of patients benefitting most from neoadjuvant or adjuvant therapy is most important before operation. This study was undertaken to determine the SUVmax in clinical stage I NSCLC and correlate it with the pathological stage of the tumour and the prognosis of the patient.
PATIENTS AND METHODS
We retrospectively reviewed the records of 674 patients who were diagnosed with NSCLC at our hospital between January 2002 and June 2005. Before surgery, the patients underwent standard staging work-ups, including chest CT, PET-CT, abdominal ultrasound and a bone scan. PET-CT was performed 60 min after the injection of the tracer [300-400 mBq of 18-fluorodeoxyglucose (FDG)] on a BIOGRAPH system (BIOGRAPH, Siemens Inc., Germany). A region of interest was drawn over the primary tumour. The SUVmax was calculated within the region of interest for each tumour. All suspicious N2 lymph nodes, identified with either CT or PET scan, were pathologically confirmed. We excluded patients with proven N2 disease or who were receiving neoadjuvant chemotherapy. After evaluation of the resectability and operability of the tumours, 152 patients with resectable clinical stage I NSCLC were included. All the patients underwent surgical resection. We examined the clinicopathological data for these patients. Oncologists or pulmonary physicians followed up the patients in clinic outpatient department. The standard follow-up consisted of chest radiography and clinical examination, with chest CT.
STATISTICAL ANALYSIS
The descriptive data are expressed as means ± standard deviations. Student's t-test was used to investigate continuous variables. The χ 2 test was used to compare categorical variables between groups. The survival from the date of surgery was calculated using Kaplan-Meier survival analysis. Multiple logistic regression was used to identify independent risk factors for patients with advanced disease. A P-value of <0.05 was considered statistically significant, and SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used for all analyses.
RESULTS
One hundred and fifty-two patients with clinical stage I NSCLC were reviewed. Among those patients with clinical preoperative PET-CT stage I, 23 patients (15.13%) were upstaged. Ten patients with preoperative clinical stage I NSCLC had pathological stage N2 disease after surgery. The mean number of dissected lymph nodes was 12. Twenty patients with preoperative clinical stage I NSCLC had pathological N1 disease after surgery. The PET-CT revealed false-negative results for N1 and N2 disease in three patients. The specificity of detection of N2 disease by PET-CT was 97.96, with 96.75% accuracy and a negative predictive value of 98.72% (Table 1 ). The specificity of detection of N1 disease by PET-CT was 99.09, with 94.87% accuracy and a negative predictive value of 95.61%. Of the 152 patients reviewed, the overall FDG-PET negative predictive value of lymph nodes was 93.19%. There were no significant differences in age, tumour histology, grade of differentiation, tumour locations (central or peripheral) between the 108 patients with pathological stage I disease and the 44 patients with non-stage I disease (Tables 2 and 3 ). Female patients predominated in the stage I group, but not in the nonstage I group. In the stage I group, patients had lower SUVmax (3.80 ± 3.17 for stage I and 5.73 ± 3.65 for non-stage I, P = 0.001), lower carcinoembryonic antigen (CEA) levels (2.86 ± 4.80 vs 9.11 ± 17.21 ng/ml, P = 0.027) and smaller tumours (2.39 ± 0.98 vs 3.73 ± 2.04 cm, P < 0.001). In the non-stage I group, 27 patients were stage II and 17 patients were stage III. The median survival was 78.75 months (68.61-88.90 months) for the stage I patients and 33.39 months (26.81-39.98 months) for the non-stage I patients (P < 0.001; Fig. 1 ). The Kaplan-Meier survival curves reduced the survival of non-stage I NSCLC. The ROC curve revealed the cutoff point of SUVmax was 3.3 to predict the pathological advanced stage. We dichotomized the patients according to this threshold. In the SUVmax <3.3 group, the patients had better differentiation of tumour (P < 0.001) and smaller size of tumour (2.24 ± 1.15 vs 3.36 ± 1.62 cm for the SUVmax ≥3.3 group, P < 0.001). Patients with higher preoperative SUVmax had a more advanced pathological stage after surgery (P < 0.001) ( Tables 4 and 5 ). The average follow-up period was 87 months. Patients with higher SUVmax in the preoperative work-up had an advanced pathological stage after surgery (SUVmax ≥3.3, odds ratio 3.246, Table 6 ). The median survival of patients with SUVmax ≥3. 
DISCUSSION
Staging by tumour node metastases and pathological classification are the key factors influencing the choice of the initial therapy for lung cancer patients. PET-CT with FDG plays an established role in the treatment of NSCLC. 18 F-FDG uptake, which reflects the tumour glucose metabolic rate, varies widely and depends on the histological type and aggressiveness of the tumour [10, 11] . Consideration of this parameter enhances the accuracy of clinical staging, improving patient selection for surgical treatment. Several previous studies have reported that preoperative SUVmax has prognostic value in the early-stage NSCLC [12, 13] . However, some recently published data have cast doubt on this proposition [9, 14, 15] . It is well known that the clinical stage of a tumour cannot fully predict its pathological stage. Many studies have been undertaken to identify the risk stratification markers and models with which to identify those patients with resectable clinical stage I NSCLC for advanced pathological disease, and who therefore stand to benefit most from adjuvant chemotherapy. Cerfolio et al. [2] correctly predicted 89% of patients with stage IV disease and 65.6% of those with stage III disease using PET-CT. In our study, there was a concordance between the pathological stage and the preoperative clinical stage in 84.87% of patients. Twenty-three (15.13%) patients had advanced pathological disease after surgery. This result is similar to the rates reported in the literature of 14.3-17% upstaged [16, 17] . Ten patients (6.59%) had postoperative N2 disease. The negative predictive values were 95.61% for N1 disease and 98.72% for N2 disease. The therapeutic strategies used to treat these 11 patients may have been altered because of their advanced-stage disease. Occult N2 disease is still an important problem in the preoperative work-up for NSCLC. Occult N2 disease has been reported in 14-16% of patients, even when the preoperative work-up included mediastinoscopy or oesophageal ultrasound fine-needle aspiration (EUS-FNA) [18] . Some authors have shown that the PET-CT data are a predictor of occult N2 disease in patients with clinical stage I NSCLC [16] . Routine mediastinoscopy or EUS-FNA in patients who were clinically staged as N0 after PET-CT may be not recommended. However, the procedure should be considered in patients clinically staged as N1 after PET-CT, and in those with adenocarcinomas, upper lobe tumours or tumours with SUVmax ≥10 [19] . Many randomized prospective studies are required to clarify the role of SUVmax in the prediction of occult N2 disease. The rationale for identifying NSCLC patients with indicators of poor prognoses is that these patients could be treated more aggressively in the first instance with neoadjuvant chemotherapy, whereas those with favourable prognostic indicators could be treated postoperatively with adjuvant chemotherapy based on their pathological stage. Cerfolio et al. [4] reported a large series of 315 patients with resected NSCLC. High SUV correlated with the stage, recurrence and survival. The SUVmax ≥10 was the best independent predictor of disease-free survival and survival. Ohtsuka et al. [8] reported that SUVmax correlated with outcome in 98 patients with stage I disease, when the analysis was limited to patients with adenocarcinoma. A value of 3.3 was found to be the optimum cutoff point for the SUVmax. It is important for the clinician to understand that SUVmax is a semi-quantitative index and may vary from one PET centre to another. Although the metabolic activity of tumours has been shown to contribute significant information in terms of prognosis [20] [21] [22] , the cutoff values for SUV measurements vary widely, making their clinical application difficult. Furthermore, histopathological markers are prognostic predictors in patients with NSCLC [23] . The tumorigenesis of NSCLC is complex, so it is impractical to simply nominate the SUVmax as an independent prognostic factor for NSCLC. Our results do not show that the tumour metabolism, as measured by PET-CT and expressed as SUVmax, yields prognostic information in patients with resected NSCLC, in either the early or advanced disease. These results are similar to those of Agarwal et al. [9] . In our study, a higher preoperative SUVmax was an independent factor predicting a pathologically advanced stage, with a hazard ratio of 3.246. However, the overall survival was not statically different between the two groups. After patient stratification according to the pathological stage, the intensity of SUV was not associated with the prognosis.
In clinical preoperative stage I lung cancer, there is a significant relationship between the growth rate, as measured with serial CT examinations, and the initial pretreatment metabolic activity, as measured by FDG uptake. This suggests that PET-CT with FDG may be used as an additional tool for determining the management of patients for whom the aggressiveness of treatment is difficult to decide [24] . Our study has shown good prognostic results for NSCLC, which may be attributable to the restricted surgical criteria and the adequate preoperative work-ups. Furthermore, the mean number of lymph node dissections in our patients was 12 because PET-CT with FDG is part of the standard pretherapeutic work-up for NSCLC. Although there was no significant difference in the serum CEA levels of the two groups (based on the intensity of SUVmax), there was a trend towards higher serum CEA levels in patients with preoperative SUVmax ≥3.3. It is easy to establish the SUVmax of a tumour and the patient's serum CEA level. We consider that the cutoff point for the preoperative SUVmax of the tumour and the patient's serum CEA level are risk stratification markers for advanced pathological disease and can identify those patients who stand to benefit most from an aggressive preoperative work-up or neoadjuvant chemotherapy, but we do not consider them prognostic factors. An aggressive preoperative work-up for occult N2 disease should be recommended, and could also circumvent inappropriate thoracotomy.
The limitations of this study are its small sample size and it was a single-institution retrospective study. More data should be made available with a larger sample of patients and long-term follow-up. Prospective clinical trials of patients with clinical stage I NSCLC, SUVmax of the primary tumour and nodal status should be investigated to identify occult N2 disease after surgery. Histopathological markers may also be helpful in further studies of potential prognostic factors. 
